Explore our new website! Designed to better serve patients, partners and the Crinetics community in the next generation of endocrinology care.

News & Events

Show:
June 28, 2021

Crinetics Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly

This trial will be one of two planned Phase 3 studies assessing the safety and efficacy of once-daily oral paltusotine in acromegaly patients that together will evaluate paltusotine in a wide cross section of acromegaly patients.

READ MORE
June 16, 2021

Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel

Garlan Adams brings over two decades of experience managing legal and compliance matters associated with the development and commercialization of...

READ MORE
May 6, 2021

First Quarter 2021 Financial Results and Corporate Update

“In the first quarter we achieved key clinical and regulatory milestones across our pipeline,” said Scott Struthers, Ph.D., Founder and...

READ MORE
April 12, 2021

Crinetics Announces Closing of Common Stock Offering

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for...

READ MORE
April 7, 2021

Crinetics Announces Pricing of Common Stock Offering

Paltusotine (formerly CRN00808), is an investigational, oral, selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly,...

READ MORE
March 30, 2021

2021 Clinical Plans, 4th Quarter, and 2020 Financial Results

Crinetics will host a webcast and conference call on Tuesday, March 30, 2021 at 4:30 p.m. ET to discuss its...

READ MORE
March 24, 2021

4QYE 2020 Financial Results Conference Call and Webcast

Event Date: March 30, 2021

READ MORE
March 24, 2021

Webcast: 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial Results

Crinetics will host a webcast and conference call on Tuesday, March 30, 2021 at 4:30 p.m. ET to discuss its...

READ MORE
March 22, 2021

Crinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021

A late-breaking e-poster and oral presentation provided details of the preclinical findings supporting the company’s development of CRN04894 and CRN04777....

READ MORE
March 12, 2021

ENDO 2021 Presentations Showcase Three Clinical Programs

Details of the improved tablet formulation of paltusotine advancing into Phase 3 studies. Preclinical evidence supporting the development of its...

READ MORE